



**FOR IMMEDIATE RELEASE**

## **Quotient Sciences Conducts Integrated Translational Pharmaceuticals® Program in U.S. With Druggability Technologies**

**Nottingham, U.K., Dec. 11, 2018** – [Quotient Sciences](#), a leading drug development services organization, and Druggability Technologies ([DRGT](#)), a specialty pharmaceutical company, announced a collaboration today to utilize Quotient’s integrated Translational Pharmaceuticals® platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT. This will be Quotient’s first Translational Pharmaceuticals program delivered from its U.S. operating facilities.

Within the program of work, DRGT is accessing Quotient’s unique Translational Pharmaceuticals platform. This involves the development of amorphous spray-dried formulations and GMP clinical trial manufacturing in Philadelphia followed by clinical dosing and taste assessment at Quotient’s clinical pharmacology unit in Miami. The program is fully adaptive, which will enable DRGT to optimize the drug product in response to emerging clinical data. Quotient will then seamlessly scale up the selected product to support pivotal patient trials.

-more-

Translational Pharmaceuticals transforms the traditional model of outsourcing to disparate contract CDMOs and CROs by integrating formulation development, real-time adaptive GMP manufacturing and clinical research. It is proven to accelerate development timelines and reduce overall costs and has been applied in over 350 programs for customers worldwide. In 2017, Quotient established the capability to run Translational Pharmaceuticals programs in the U.S. Following a Critical Path Innovation Meeting with the FDA's Office of Translational Sciences, and meetings with local institutional review boards, Quotient is now delivering programs in the U.S.

"We have significantly expanded our CDMO and CRO operations in the U.S. and are now performing integrated programs in the world's largest R&D market," said [Mark Egerton](#), Ph.D., CEO of Quotient. "This offers significant advantages to our customers. We are delighted to support DRGT on accelerating DRGT-46 as a new treatment for acute and chronic pain."

[Gábor Heltovics](#), CEO of DRGT, added, "We are very pleased to be working with Quotient on this accelerated development project with our proprietary super-API technology. Quotient's tight integration of formulation, manufacturing and clinical research services has enabled DRGT to execute an efficient development plan with a single outsourcing partner and, most importantly, reduce our time to market."

Quotient's comprehensive drug product expertise spans all types of oral dosage forms, a broad range of solubilization technologies and high potency handling capabilities.

#### **About Quotient Sciences**

Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, delivers innovative, customized solutions for over 150 pharmaceutical and biotech customers through both individual and integrated services. Quotient has more than 800 employees across six operating sites in the U.K. and U.S. Visit [quotientsciences.com](http://quotientsciences.com).

###